Sangamo Therapeutics Inc (NASDAQ:SGMO) has been given an average rating of “Hold” by the ten brokerages that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $18.80.
SGMO has been the subject of several recent research reports. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, November 6th. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 10th. Wedbush set a $11.00 price objective on Sangamo Therapeutics and gave the stock a “hold” rating in a report on Monday, November 19th. JPMorgan Chase & Co. cut Sangamo Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $11.00 in a report on Wednesday, November 14th. Finally, Guggenheim lowered Sangamo Therapeutics from a “buy” rating to a “neutral” rating and set a $18.00 target price for the company. in a research report on Friday, November 9th.
In other news, VP Edward R. Conner sold 5,000 shares of the business’s stock in a transaction dated Monday, January 7th. The stock was sold at an average price of $12.33, for a total transaction of $61,650.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 25,000 shares of company stock valued at $281,500 over the last 90 days. Corporate insiders own 1.20% of the company’s stock.
NASDAQ:SGMO traded up $0.49 on Friday, hitting $8.81. 1,099,390 shares of the stock were exchanged, compared to its average volume of 2,471,546. The stock has a market capitalization of $849.41 million, a P/E ratio of -12.59 and a beta of 2.84. Sangamo Therapeutics has a 52 week low of $6.26 and a 52 week high of $27.50. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Further Reading: Quiet Period
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.